BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8752145)

  • 1. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.
    Han Y; Caday CG; Nanda A; Cavenee WK; Huang HJ
    Cancer Res; 1996 Sep; 56(17):3859-61. PubMed ID: 8752145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate.
    Han Y; Caday CG; Umezawa K; Nanda A
    Oncol Res; 1997; 9(11-12):581-7. PubMed ID: 9563005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells.
    Sion-Vardy N; Vardy D; Rodeck U; Kari C; Levin RM; Malkowicz SB
    J Surg Res; 1995 Dec; 59(6):675-80. PubMed ID: 8538164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
    Lei W; Mayotte JE; Levitt ML
    Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor.
    El-Obeid A; Hesselager G; Westermark B; Nistér M
    Biochem Biophys Res Commun; 2002 Jan; 290(1):349-58. PubMed ID: 11779176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.
    Brunton VG; Carlin S; Workman P
    Anticancer Drug Des; 1994 Aug; 9(4):311-29. PubMed ID: 7916899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes.
    Ben-Bassat H; Rosenbaum-Mitrani S; Hartzstark Z; Shlomai Z; Kleinberger-Doron N; Gazit A; Plowman G; Levitzki R; Tsvieli R; Levitzki A
    Cancer Res; 1997 Sep; 57(17):3741-50. PubMed ID: 9288782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
    Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
    Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.
    Schmidt-Ullrich RK; Mikkelsen RB; Dent P; Todd DG; Valerie K; Kavanagh BD; Contessa JN; Rorrer WK; Chen PB
    Oncogene; 1997 Sep; 15(10):1191-7. PubMed ID: 9294612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
    Yoshinaka Y; Katoh I; Kyushiki H; Sakamoto Y
    Exp Cell Res; 1995 Jul; 219(1):21-8. PubMed ID: 7543053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation.
    Gschwind A; Prenzel N; Ullrich A
    Cancer Res; 2002 Nov; 62(21):6329-36. PubMed ID: 12414665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposing effects of tyrosine kinase inhibitors on mineralization of normal and tumor bone cells.
    Klein BY; Tepper SH; Gal I; Shlomai Z; Ben-Bassat H
    J Cell Biochem; 1997 Jun; 65(3):420-9. PubMed ID: 9138097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the cytotoxic activity of tumor necrosis factor by protein tyrosine kinase and protein tyrosine phosphatase inhibitors.
    Mishra S; Mathur R; Hamburger AW
    Lymphokine Cytokine Res; 1994 Apr; 13(2):77-83. PubMed ID: 8061118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tyrphostin on cell growth and tyrosine kinase activity of epidermal growth factor receptor in human gliomas.
    Miyaji K; Tani E; Shindo H; Nakano A; Tokunaga T
    J Neurosurg; 1994 Sep; 81(3):411-9. PubMed ID: 8057149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.